PMID- 32050864
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 1545-0848 (Electronic)
IS  - 1055-0887 (Linking)
VI  - 38
IP  - 2
DP  - 2020 Apr-Jun
TI  - Randomized trial to assess safety/feasibility of memantine administration during 
      residential treatment for alcohol use disorder: a pilot study.
PG  - 91-99
LID - 10.1080/10550887.2020.1721404 [doi]
AB  - The N-methyl-D-aspartate receptor (NMDAr) system is critically involved in the 
      pathogenesis and neurobehavioral sequelae of alcohol use disorder (AUD), and 
      constitutes a potential pharmacotherapeutic target. Memantine (Namenda) is an 
      FDA-approved NMDAr antagonist with suggested utility in AUD, however its safety 
      and tolerability during long-term administration among recently-detoxified 
      patients remains uncharacterized. This pilot study assessed safety, feasibility, 
      and several secondary measures of interest, during a 4-week period of residential 
      AUD treatment. Participants (N = 18) met diagnostic criteria for AUD. A 
      double-blind, placebo-controlled, escalating-dose design was utilized. 
      Assessments of medication side-effects were conducted weekly. At intake, week 2, 
      and study completion, participants completed a battery assessing affective 
      symptomatology, craving, and neurocognitive function. Medication groups reported 
      equivalent side effects and severity. Medication compliance was high, and did not 
      differ by group. No memantine effects were observed in secondary outcome 
      measures. Memantine maintains a profile of high tolerability and low side-effects 
      during post-detoxification AUD treatment. These data suggest a more aggressive 
      dosing/escalation schedule may be used safely in future trials designed to 
      ascertain improvements in neurocognitive function, affect, and/or craving as 
      primary measures.
FAU - Lewis, Ben
AU  - Lewis B
AD  - Department of Psychiatry, University of Florida, Gainesville, FL, USA.
AD  - Center for Addiction Research & Education, University of Florida, Gainesville, 
      FL, USA.
FAU - Merlo, Lisa
AU  - Merlo L
AD  - Department of Psychiatry, University of Florida, Gainesville, FL, USA.
AD  - UF Health Florida Recovery Center, Gainesville, FL, USA.
AD  - Center for Addiction Research & Education, University of Florida, Gainesville, 
      FL, USA.
FAU - Greene, William
AU  - Greene W
AD  - Department of Psychiatry, University of Florida, Gainesville, FL, USA.
AD  - UF Health Florida Recovery Center, Gainesville, FL, USA.
FAU - Welch, Emily
AU  - Welch E
AD  - Department of Psychiatry, University of Florida, Gainesville, FL, USA.
FAU - Nixon, Sara Jo
AU  - Nixon SJ
AUID- ORCID: 0000-0003-1179-2851
AD  - Department of Psychiatry, University of Florida, Gainesville, FL, USA.
AD  - Center for Addiction Research & Education, University of Florida, Gainesville, 
      FL, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200212
PL  - England
TA  - J Addict Dis
JT  - Journal of addictive diseases
JID - 9107051
RN  - 0 (Dopamine Agents)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Adult
MH  - Alcoholism/*drug therapy
MH  - Dopamine Agents/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Memantine/*pharmacology
MH  - Middle Aged
MH  - Pilot Projects
MH  - Residential Treatment
OTO - NOTNLM
OT  - Memantine
OT  - Namenda
OT  - alcohol use disorder
OT  - safety
OT  - side effects
EDAT- 2020/02/14 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/02/14 06:00
PHST- 2020/02/14 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
PHST- 2020/02/14 06:00 [entrez]
AID - 10.1080/10550887.2020.1721404 [doi]
PST - ppublish
SO  - J Addict Dis. 2020 Apr-Jun;38(2):91-99. doi: 10.1080/10550887.2020.1721404. Epub 
      2020 Feb 12.